For international customers currently using our coronary technology, we’re happy to report that coinciding with its presentation at TCT 2019 today, the DISRUPT CAD II study has also been simultaneously published by the AHA journal, Circulation: Cardiovascular Interventions.
The publication greatly increases the amount of published peer-reviewed data available for our coronary technology. It adds 120 patients to the existing 60 that were enrolled in DISRUPT CAD I, while confirming its promising initial outcomes. It’s a major milestone for the company as we continue to build the appropriate clinical evidence to fully validate our technology.
Congratulations once again to all of those involved in the study, especially the DISRUPT CAD II investigators for their dedication and work on such a well-executed study.
Important Safety Information - Coronary
Caution: In the United States, Shockwave C2 Coronary IVL catheters are investigational devices, limited by United States law to investigational use. DISRUPT CAD III Study
Shockwave C2 Coronary IVL catheters are commercially available in certain countries outside the U.S. Please contact your local Shockwave representative for specific country availability. The Shockwave C2 Coronary IVL catheters are indicated for lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic de novo coronary arteries prior to stenting. For the full IFU containing important safety information please visit: https://shockwavemedical.com/clinicians/international/coronary/shockwave-c2/